AN2 Therapeutics Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

ANTX$4.00+1.1%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and per share amounts)

	March 31,	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$24,693	$15,647
Short-term investments	89,517	91,648
Prepaid expenses and other current assets	2,103	3,212
Total current assets	116,313	110,507
Long-term investments	3,904	27,194
Other assets, long-term	1,043	1,043
Total assets	$121,260	$138,744
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$2,433	$2,676
Accrued compensation	995	4,018
Accrued liabilities	6,914	6,681
Other current liabilities	321	668
Total liabilities	10,663	14,043
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023	—	—
Common stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 29,815,663 and 29,741,445 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	—	—
Additional paid-in capital	281,616	278,881
Accumulated other comprehensive gain	53	275
Accumulated deficit	(171,072)	(154,455)
Total stockholders’ equity	110,597	124,701
Total liabilities and stockholders’ equity	$121,260	$138,744

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.